Affordable Access

Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.

Authors
  • Anglin, P
  • Strauss, B A
  • Brandwein, J M
Type
Published Article
Journal
Leukemia & lymphoma
Publication Date
Nov 01, 1993
Volume
11
Issue
5-6
Pages
469–472
Identifiers
PMID: 7510192
Source
Medline
License
Unknown

Abstract

Hematopoietic growth factors, including granulocyte colony-stimulating factor (G-CSF), are being increasingly used to prevent chemotherapy-induced neutropenia. We report a patient with aggressive non-Hodgkin's lymphoma who was successfully supported with G-CSF through a weekly VACOP-B chemotherapy regimen. The patient had become severely neutropenic at week 3, requiring a one-week delay. For the remainder of the treatment, G-CSF at a dose of 4 micrograms/kg/day was administered daily over 4 days after week 4, then over 3 days thereafter, beginning the day after the non-myelosuppressive weeks (vincristine/bleomycin). A total of 5 such G-CSF courses were given, with no further neutropenia despite administration of full chemotherapy doses on schedule. This case suggests that, at least with the VACOP-B regimen, chemotherapy-induced neutropenia can be prevented using much lower quantities of G-CSF than has been reported using other regimens.

Report this publication

Statistics

Seen <100 times